A Tale of Two Markets: Micro-Cap Chaos Amidst Nasdaq Correction

Nasdaq correction sparks wild micro-cap swings. Artelo Biosciences surges 300% on funding & pipeline news, while top gainers are reverse split mirages. See the data and analysis.

As the Nasdaq Composite officially entered correction territory this Friday, the most dramatic price action was reserved for the smallest stocks. Soaring oil prices above $110 per barrel, climbing bond yields, and geopolitical tensions surrounding the Strait of Hormuz triggered a flight from risk. Meanwhile, reverse stock splits for two companies generated illusory triple-digit gains, and a single biotech firm provided a substantive rally amidst the volatility.

The day’s performance tables served as a textbook illustration of both the pitfalls and opportunities within the micro-cap universe.

Asset	Price	Change	Sector
Creative Media & Community Trust	$0.59	+748.6 %	Real Estate
INVO Fertility	$2.64	+357.5 %	Healthcare
Artelo Biosciences	$12.79	+300.9 %	Healthcare
Veritone	€1.63	-36.1 %	Technology
Shuttle Pharmaceuticals	$0.58	-32.4 %	Healthcare
AmpliTech	$1.93	-27.4 %	Technology

Artelo Biosciences: A 300% Surge Fueled by Capital and Catalysts

In a sea of technical moves, Artelo Biosciences delivered a rally with fundamental backing. Its equity advanced 300.9% to $12.79. The catalyst was a definitive agreement for a private placement of 3.19 million common shares plus warrants for an additional 6.38 million shares, priced at a combined $3.45 per unit. Gross proceeds are estimated at $11 million, with closing expected by March 30.

These funds are earmarked for working capital and repaying bridge loans. This news followed an announcement two days prior regarding the expanded development of ART27.13 as an adjunct therapy to GLP-1 treatments, including a patent filing and the initiation of a non-clinical study. The company also highlighted an entry into the $16.3 billion glaucoma market via an externally funded clinical trial. For a previously depressed stock, this combination of fresh capital and pipeline updates proved explosive.

The Illusion of Gains: Reverse Splits Dominate the Winners' List

The day's largest percentage gains were mathematical artifacts, not reflections of business improvement.

Creative Media & Community Trust (CMCT) soared 748.6% to $0.59. This move was solely the result of a 1-for-10 reverse stock split effective March 26. Beyond this corporate action, the real estate trust has recently executed balance sheet measures, converting approximately 1.96 million Series A, 7.73 million Series A1, and nearly 21,800 Series D preferred shares into common stock. This is expected to improve annual Funds From Operations (FFO) by about $16 million. However, the company reported a net loss of $17.7 million for Q4 2025. The sale of its credit segment generated net proceeds of roughly $31.2 million. The stock remains firmly in penny stock territory.

INVO Fertility followed a similar pattern, climbing 357.5% to $2.64 driven by a 1-for-5 reverse split. Shares now trade under the same "IVF" ticker on a consolidated basis, with approximately 1.62 million common shares outstanding post-split. Such maneuvers are often attempts to maintain minimum listing requirements for the Nasdaq, a signal seasoned market participants view cautiously. Operationally, the fertility specialist continues to focus on clinic expansion and its INVOcell procedure but released no fresh news to justify the price move.

The Losers: Earnings Disappointments Meet a Risk-Averse Mood

On the declining side, disappointing financial results were met with severe punishment.

Veritone led the losers, plunging 36.1%. The AI software provider's Q4 2025 results, released the prior evening, missed expectations across the board:
* Q4 Revenue: $18.1 million, a 19.3% year-over-year decline and far below the $35.0 million consensus.
* Net Loss: $37.0 million, worsening by 216% from the prior year.
* Diluted EPS: -$0.41 versus analyst expectations of -$0.05.

Compounding matters were accounting uncertainties related to a $12.9 million data rights transaction that could materially shift reported results. The company's unusually wide preliminary revenue range for Q4 signaled poor visibility. Despite guiding for 2026 revenue of $130-$145 million and reporting a Veritone Data Refinery backlog exceeding $50 million, the disastrous current figures overwhelmed any forward-looking optimism.

AmpliTech Group fell 27.4% to $1.93 following its quarterly report. While revenue of $4.48 million slightly exceeded the $4.30 million estimate, the earnings per share loss of -$0.14 was double the anticipated -$0.07. The market focused squarely on the larger-than-expected loss. A short interest of 21.8% suggests bearish bets were already in place, accelerating the sell-off post-announcement.

Shuttle Pharmaceuticals dropped another 32.4% to $0.58, matching its 52-week low. The stock has lost 46% of its value in one month, trading far below its 50-day ($1.48) and 200-day ($2.38) moving averages. The decline is attributed to a recently announced capital raise involving 2.24 million common shares and pre-funded warrants for 4.76 million more shares, expected to yield gross proceeds of $3.5 million. This substantial dilution continues to pressure the stock, overshadowing a March 26 technology update for its molecule.ai platform.

Macro Pressures Amplify Micro-Cap Volatility

The trading session on March 27 highlighted a stark divide. On a macro level, oil above $110, a 10-year Treasury yield at 4.46%, and escalating trade tensions with China weighed on sentiment, pulling down major tech names.

Within the micro-cap segment, these pressures were magnified, revealing two clear patterns:
1. Reverse Splits Create Mirage: The triple-digit gains for CMCT and INVO Fertility reflect corporate arithmetic, not operational progress.
2. Earnings Misses Are Punished Severely: As seen with Veritone and AmpliTech, the margin for error vanishes during risk-off phases, with disappointing results triggering outsized declines.

Artelo Biosciences stood as the exception, where substantive corporate developments drove its rally. For as long as geopolitical uncertainty and inflation concerns persist, the environment for technology-heavy growth stocks will remain challenging. A de-escalation in the Strait of Hormuz and retreating energy prices would be prerequisites for a broader market recovery.